
|Slideshows|September 30, 2016
Neuro News Roundup: Potential MS Therapies
Author(s)Mark L. Fuerst
Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.
Advertisement
Amiselimod, a second generation spin-off of fingolimod, may be a new potential treatment in MS and potentially other immune-mediated inflammatory diseases. Alemtuzumab may be a useful addition to the armamentarium as first-line treatment for relapsing-remitting MS (RRMS). Arbaclofen extended-release tablets may be more effective at decreasing spasticity related to MS than the commonly used spasticity-fighting drug baclofen.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Previewing Expected FDA Decisions in Neurology for 2026
2
Linking Exercise to Dopamine and Motor Performance in Parkinson Disease
3
NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care?
4
NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease
5


























